GE HealthCare and RadNet’s DeepHealth Division Sign Letter of Intent to Advance Innovation and Adoption of AI-Powered Imaging ...

The Europe interventional ultrasound market is projected to reach $1.08 billion by 2035 from $604.0 million in 2024, growing at a CAGR of 5.62% during the forecast period 2025-2035.

GE HealthCare (Nasdaq: GEHC) announced that it and RadNet subsidiary DeepHealth plan to expand their existing strategic.

Focus on Application, End User, and Country Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The Europe interventional ...

Pulsenmore’s at-home ultrasound platform, Pulsenmore ES, has received de novo authorisation from the US Food and Drug Administration (FDA).

Revolutionizing Diagnostic PrecisionThe global AI in ultrasound imaging market is poised for impressive growth, projected to expand at a CAGR of around 22% over the next five years. This surge is ...

Pulsenmore announced today that it received FDA de novo clearance for its home-use prenatal ultrasound platform.

Although GE HealthCare stock has lagged behind the broader market over the past year, analysts remain moderately bullish ...

The Pain Clinic celebrates its Foundation Day, marking the 12 November 2013 laying of the foundation stone of its current building by Prof. P. Prithvi Raj, pioneer of interventional pain medicine and ...

Pulsenmore CEO Dr. Elazar Sonnenschein said, ‘Our device has been approved in the 510k de novo pathway. This means that there ...

GE HealthCare Techs has received a total of 5 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $85.0, the consensus suggests a potential 8.49% ...